ArticleCase reports in dermatology
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 304 citations in OpenAlex.
- Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.JAMA dermatology · 2018Pooled it
- A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.Archives of dermatological research · 2023Trial
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata.Skin health and disease · 2023Article
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.Clinical, cosmetic and investigational dermatology · 2021Review
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.Dermatology and therapy · 2019Article
- JAK Inhibitors for Treatment of Alopecia Areata.The Journal of investigative dermatology · 2018Review
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature.JAAD case reports · 2018Article
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.Clinical reviews in allergy & immunology · 2018Review
- Role of janus kinase inhibitors in the treatment of alopecia areata.Drug design, development and therapy · 2018Review
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Nature reviews. Drug discovery · 2017Article
- Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series.Rheumatology and therapy · 2017Article
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Nature reviews. Drug discovery · 2017Review
- Alopecia Areata: An Update on Treatment Options for Children.Paediatric drugs · 2017Review
- Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment.Singapore medical journal · 2017Article
- JAK inhibitors in dermatology: The promise of a new drug class.Journal of the American Academy of Dermatology · 2017Review
- Alopecia areata.Nature reviews. Disease primers · 2017Review
- An unusual case of tricho-dento-osseous syndrome.Dental research journalArticle
- A Comment on JAK Inhibitors for Treatment of Alopecia Areata.International journal of trichologyArticle
- Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report.Case reports in dermatologyArticle
- Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options.International journal of trichologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lymphocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and subsequently inhibit further hair growth. Depending on the extent of involvement, alopecia areata can be associated with a dramatic reduction of quality of life. Currently, no targeted treatment option is available, and topical immune therapies or immunosuppressive drugs are typically used with mixed success. Recently, several cases of alopecia areata responding to Janus kinase inhibitors were published. Here, we report on a businessman with alopecia areata universalis who was treated with tofacitinib. We observed initial signs of hair regrowth in the same timeframe as previously reported, but efficacy quickly waned again, leading to renewed effluvium. Thus, even though tofacitinib and ruxolitinib are a promising new treatment option, we have yet to learn more about their potential role in each particular patient's individual treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.